Pfizer, BIND Therapeutics Partner to Develop Medicines

Apr 04, 2013

Wall Street Journal

BIND Therapeutics announced that Pfizer Inc. has agreed to pay at least $160 million per drug as part of a collaboration to develop targeted medicines using nanotechnology which use particles measured in billionths of a meter.

BIND is developing an experimental group of targeted, programmable medicines called Accurins to treat cancer, heart disease and inflammatory disorders. Read the full story